Key result
Triple antithrombotic therapy comprises ~65% of discharge prescriptions over dual therapies.
Why the study?
The study was conducted to assess the current pharmacological management of patients with AF and ACS undergoing coronary stenting.
What is the contemporary pharmacological management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting?
Observational (n=598)
Yes
What is the contemporary pharmacological management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting?
Answers are grounded in this paper and cite their sources.
Despite randomized trial data supporting dual antithrombotic therapy, triple antithrombotic therapy remains the most common strategy at discharge for ACS patients with AF undergoing PCI in contemporary practice.
OBJECTIVE: The aim of the study was to assess current management of patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing coronary stenting. DESIGN: Non-interventional, prospective, nationwide study. SETTING: 76 private or public cardiology centres in Italy. PARTICIPANTS: Patients with ACS with concomitant AF undergoing percutaneous coronary intervention (PCI). PRIMARY AND SECONDARY OUTCOME MEASURES: To obtain accurate and up-to-date information on pharmacological management of patients with AF admitted for an ACS and undergoing PCI with stent implantation. RESULTS: Over a 12-month period, 598 consecutive patients were enrolled: 48.8% with AF at hospital admission and 51.2% developing AF during hospitalisation. At discharge, a triple antithrombotic therapy (TAT) was prescribed in 64.8%, dual antiplatelet therapy (DAPT) in 25.7% and dual antithrombotic therapy (DAT) in 8.8% of patients. Among patients with AF at admission, TAT and DAT were more frequently prescribed compared with patients with new-onset AF (76.3% vs 53.8% and 12.5% vs 5.3%, respectively; both p<0.0001), while a DAPT was less often used (11.2% vs 39.5%; p<0.0001). At multivariable analysis, a major bleeding event (OR: 5.40; 95% CI: 2.42 to 12.05; p<0.0001) and malignancy (OR: 5.11; 95% CI: 1.77 to 14.78; p=0.003) resulted the most important independent predictors of DAT prescription. CONCLUSIONS: In this contemporary registry of patients with ACS with AF treated with coronary stents, TAT still resulted as the antithrombotic strategy of choice, DAT was reserved for high bleeding risk and DAPT was mainly prescribed in those developing AF during hospitalisation. TRIAL REGISTRATION NUMBER: NCT03656523.
No takes yet. Share an insight, caveat, or question.
Luca et al. (2020) conducted an observational in Acute coronary syndrome (ACS) with concomitant atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) (n=598). Antithrombotic management strategies was evaluated on Prescription rate of triple antithrombotic therapy (TAT) at discharge. At discharge, triple antithrombotic therapy was prescribed in 64.8% of patients, dual antiplatelet therapy in 25.7%, and dual antithrombotic therapy in 8.8%.
Synapse has enriched 10 related papers. Consider them for comparative context: